Torrent opens exclusive human insulin unit for Novo Nordisk
14 Nov 2009
Torrent Pharmaceuticals Ltd has commissioned a new facility to manufacture human insulin at its Indrad manufacturing complex exclusively for supply to global healthcare major Novo Nordisk, the company said in a filing with the Bombay Stock Exchange.
Gujarat minister for health and family welfare and tourism, Jayanarayan Vyas inaugurated the facility on Saturday in the presence of Jesper Holland, senior vice president of Novo Nordisk, the release added.
The new integrated manufacturing facility, which conforms to international quality standards in manufacturing and vial packaging, will have a capacity to manufacture 26 million vials annually.
With a team of over 560 scientists, the Torrent R & D centre offers services in the areas of drug research and discovery, generic drug development and new drug delivery systems/value-added generics.
The $40 million Torrent R&D centre currently has seven discovery projects in pipeline - three in diabetes and related complications, one in cerebro-vascular, two in obesity and one in cardio-vascular.
Torrent has received 123 patent rights across major markets such as the US, Japan, Europe, Czech Republic, Australia, Hong Kong, Russia and India. The company has filed 219 patents for NCEs in all major markets worldwide.